FDA to Review Peptides: What Med Spa Professionals Should Know Ahead of the July 23–24 Meeting

The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) will meet July 23-24 to discuss whether several peptide substances should be considered for inclusion on the Section 503A Bulks List, an important regulatory pathway for pharmacy compounding. While the meeting will not approve or ban peptide products, its recommendations could influence how certain peptides are compounded and accessed in the future.

As interest grows in peptides across wellness, longevity and aesthetic medicine, the industry is discussing ongoing questions about safety, sourcing, evidence and patient demand.

What peptides are the FDA reviewing?

According to the FDA agenda, the committee will discuss seven peptide-related substances over two days, including:

• BPC-157
• KPV
• TB-500
• MOTS-c
• Semax
• Epitalon
• Emideltide (DSIP)

The committee will evaluate scientific evidence, safety information and clinical need as it considers whether these substances meet criteria for inclusion on the 503A Bulks List.

What the meeting has the power to do

One of the biggest misconceptions surrounding the meeting is that the FDA is “approving” or “banning” peptides. That is not what is happening.

PCAC provides recommendations to the FDA. Those recommendations are nonbinding and represent one step in a broader regulatory process. Even if a peptide receives a favorable recommendation, additional FDA action would still be required before any regulatory changes take effect.

Prior to April 22, 2026, the FDA placed these peptides as Category 2 Bulk drug substances, which have since been nominated for the 503A compounding list. As background, the Food and Drug Act in sec 503A provides that bulk drug substances that either 1) lack a USP or NF monograph, or 2) are not components of FDA-approved drug products, cannot be used in compounding unless they appear on a list created under Section 503A. These peptides are not FDA approved and do not have a monograph, so that leaves the bulk list as the only option.

However, this list is yet to be finalized and until the FDA evaluates and publishes a final rule regarding a substance’s inclusion on the 503A bulks list, the FDA has stated that it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians who compound drugs using bulk substances provided the following circumstances are met:

1. The bulk drug substance is listed in 503A Category 1 on the FDA’s website.
2. The manufacturer and subsequent manufacturers are registered under Section 510 of the FD&C Act.
3. The bulk drug substance has a valid Certificate of Analysis (COA).
4. The compounded drug complies with all other Section 503A requirements.

Since these peptides were Category 2, the FDA could take action. What this upcoming meeting (and possibly other meetings before Feb ’27) is going to determine is which of the lists they should fall in. If they are added to the Category 1 list, then that could open the door for pharmacies to compound the peptides.

Basically, this is just a do-over or reevaluation for these substances to place them in the right category.

Why providers should pay attention

Peptides have become increasingly visible across wellness, recovery, longevity and aesthetic medicine. Demand continues to grow despite ongoing questions about:

• Human clinical trials
• Evidence of efficacy
• Appropriate dosing
• Long-term safety
• Product quality
• Compounding standards
• Supply-chain integrity

For providers, the meeting may offer clues about how regulators view these challenges and whether future guidance could affect access to compounded peptide therapies.

Questions still remain

The FDA meeting is unlikely to settle the broader debate around peptides.

Many substances being discussed have enthusiastic supporters as well as critics who point to limited human clinical data. At the same time, some industry stakeholders argue that restrictions have pushed consumers toward gray-market sourcing channels that may create additional safety concerns.

For now, med spa professionals should focus on staying informed, monitoring regulatory developments and evaluating any peptide-related offerings through the lens of patient safety, evidence and compliance.

AmSpa will continue monitoring the meeting and sharing updates as information becomes available.